2025
LUMATEPERONE TREATMENT FOR MAJOR DEPRESSIVE EPISODES WITH MIXED FEATURES IN MAJOR DEPRESSIVE DISORDER AND BIPOLAR I OR BIPOLAR II DISORDER
Bhagwagar *, Kozauer S, Earley W, Chen C, Huo J, Stahl S, McIntyre R, Durgam S. LUMATEPERONE TREATMENT FOR MAJOR DEPRESSIVE EPISODES WITH MIXED FEATURES IN MAJOR DEPRESSIVE DISORDER AND BIPOLAR I OR BIPOLAR II DISORDER. The International Journal Of Neuropsychopharmacology 2025, 28: i19-i19. PMCID: PMC11815047, DOI: 10.1093/ijnp/pyae059.033.Peer-Reviewed Original ResearchBipolar depressionBipolar II disorderII disorderLumateperone treatmentMDD populationBipolar IDSM-5Baseline to dayDSM-5-TRIncreased suicide riskMixing featuresPoor treatment responseAdverse eventsMADRS totalTreatment-emergent adverse eventsCGI-S scoresHypomanic symptomsDepressive disorderExtrapyramidal symptomsTreat schizophreniaDepressive episodeConsistent with prior studiesLumateperoneSuicide riskMDDAntidopaminergic medications in Huntington's disease
Tan A, Geva M, Goldberg Y, Schuring H, Sanson B, Rosser A, Raymond L, Reilmann R, Hayden M, Anderson K. Antidopaminergic medications in Huntington's disease. Journal Of Huntington's Disease 2025, 14: 16-29. PMID: 39973394, DOI: 10.1177/18796397241304312.Peer-Reviewed Original ResearchConceptsAntidopaminergic medicationsSymbol Digit Modalities TestHuntington's diseaseComposite Unified Huntington’s Disease Rating Scale,Unified Huntington's Disease Rating ScaleExtrapyramidal symptomsWord readingHuntington's Disease Rating ScaleVMAT2 inhibitorsBehavioral impairmentsBehavioral disordersCognitive dysfunctionCognitive functionRating ScaleADM useDisease Rating ScaleHD symptomsTotal functional capacityModal testingMotor disturbancesFunctional impairmentProgressive neurodegenerative disorderMounting body of evidenceSide effectsBody of evidence
2024
Psychopharmacological Treatment of Schizophrenia
Singh N, Ganesh S, D'Souza D. Psychopharmacological Treatment of Schizophrenia. 2024, 729-737. DOI: 10.1016/b978-0-323-95702-1.00177-9.Peer-Reviewed Original ResearchAntipsychotic drugsPositive symptoms of schizophreniaPharmacological treatment of schizophreniaTreatment-resistant schizophreniaPharmacological treatmentSymptoms of schizophreniaTreatment of schizophreniaAcute psychotic episodeNeuroleptic malignant syndromeNegative symptomsPositive symptomsExtrapyramidal symptomsPsychotic episodeCognitive deficitsCognitive symptomsMalignant syndromeSchizophreniaPrevent relapseSide effectsMaintenance treatmentLong-actingDopamineAssociated with significant side effectsMedication adherenceProportion of patients
2020
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia. New England Journal Of Medicine 2020, 382: 1497-1506. PMID: 32294346, DOI: 10.1056/nejmoa1911772.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdultAntipsychotic AgentsDouble-Blind MethodDrug Administration ScheduleFemaleHumansLeast-Squares AnalysisMaleReceptors, Dopamine D2Receptors, G-Protein-CoupledSchizophreniaSchizophrenic PsychologySerotonin 5-HT1 Receptor AgonistsSeverity of Illness IndexTreatment OutcomeConceptsTrace amine-associated receptor 1Week 4Negative Symptom ScaleAcute exacerbationPlacebo groupBrief Negative Symptom ScaleTotal scoreSymptom ScaleClinical Global Impression-Severity ScaleEnd pointPrimary end pointSecondary end pointsSudden cardiac deathPANSS total scoreTreatment of schizophreniaDopamine D2 receptorsTreatment of psychosisType 1A receptorMean total scoreLevels of lipidsGastrointestinal symptomsAdverse eventsCardiac deathExtrapyramidal symptomsPrimary outcome
2019
Parkinson's Disease Dementia and Lewy Body Disease
Sezgin M, Bilgic B, Tinaz S, Emre M. Parkinson's Disease Dementia and Lewy Body Disease. Seminars In Neurology 2019, 39: 274-282. PMID: 30925619, DOI: 10.1055/s-0039-1678579.Peer-Reviewed Original ResearchConceptsParkinson's disease dementiaDisease dementiaCognitive symptomsBehavioral symptomsLewy body diseaseCerebrospinal fluid biomarkersTime of onsetAutonomic dysfunctionExtrapyramidal symptomsBody diseaseClinical featuresNeuropathological findingsNeuropsychiatric symptomsRandomized trialsClinical pictureLewy bodiesFluid biomarkersClinical differentiationSleep disordersCholinesterase inhibitorsCognitive impairmentSymptomsDementiaNeurodegenerative disordersDLB
2018
Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects
Olten B, Bloch MH. Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2018, 84: 272-281. PMID: 29410000, DOI: 10.1016/j.pnpbp.2018.01.023.Peer-Reviewed Original ResearchConceptsRisk of sedationExtrapyramidal side effectsM4 receptorsReceptor binding profileWeight gainAntipsychotic medicationSide effectsGeneric inverse variance methodReceptor affinityAffinity of antipsychoticsIndividual antipsychotic medicationsInverse variance methodTreatment of schizophreniaExtrapyramidal symptomsQTc prolongationM1 receptorsProlactin increaseQT prolongationAntipsychotic agentsH1 receptorsHigh riskMedicationsSedationBinding profileReceptors
2013
Clinical potential of cariprazine in the treatment of acute mania.
Altınbaş K, Guloksuz S, Oral E. Clinical potential of cariprazine in the treatment of acute mania. Psychiatria Danubina 2013, 25: 207-13. PMID: 24048386.Peer-Reviewed Original ResearchConceptsAcute manic episodeAdverse eventsManic episodesTreatment-emergent adverse eventsD3 receptor activityFlexible-dose studyCommon adverse eventsSerious adverse eventsCommon side effectsAdditional therapeutic benefitSecond-generation antipsychoticsCariprazine treatmentDopamine agonismPlacebo armAcute maniaExtrapyramidal symptomsQTc prolongationGeneration antipsychoticsHistamine H1Novel antipsychoticsProlactin increaseMetabolic disturbancesClinical trialsClinical dataDopamine D2
2011
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH. Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. New England Journal Of Medicine 2011, 364: 842-851. PMID: 21366475, DOI: 10.1056/nejmoa1005987.Peer-Reviewed Original ResearchConceptsInjectable risperidoneOral antipsychoticsQuality of lifeSchizoaffective disorderPsychiatrist's choiceSecond-generation antipsychotic agentsMore adverse eventsMore extrapyramidal symptomsPrimary end pointNeurologic side effectsExtrapyramidal adverse effectsRate of hospitalizationVeterans Affairs systemSocial Performance ScaleAdverse eventsExtrapyramidal symptomsOral treatmentAntipsychotic agentsUnstable diseasePsychiatric symptomsHigh riskHospitalizationSide effectsPatientsPsychiatric hospital
2010
Risperidone-Induced Bulbar Palsy-like Syndrome
Sico JJ, Patwa H. Risperidone-Induced Bulbar Palsy-like Syndrome. Dysphagia 2010, 26: 340-343. PMID: 20922432, DOI: 10.1007/s00455-010-9307-z.Peer-Reviewed Original ResearchConceptsAcute dystonic reactionsDrug-induced parkinsonismCases of dysphagiaChlorpromazine useSymptomatic hyperprolactinemiaAcute onsetMedication discontinuationPharyngeal dysfunctionAssociated morbidityDystonic reactionsAspiration eventsExtrapyramidal symptomsOropharyngeal dysphagiaFacial diplegiaCase reportComplete resolutionDysphagiaPrior historyDose changesSide effectsRisperidonePatientsSyndromeHyperprolactinemiaDiplegiaClinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation Scale
Sewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH. Clinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation Scale. Schizophrenia Research 2010, 124: 1-12. PMID: 20855185, DOI: 10.1016/j.schres.2010.08.036.Peer-Reviewed Original ResearchConceptsNeurological Evaluation ScaleAbnormal Involuntary Movement ScaleDigit Symbol Substitution TaskWisconsin Card Sorting TestNeurologic deficitsClinical significanceExtrapyramidal Symptom Rating ScaleMore extrapyramidal symptomsBarnes Akathisia ScaleDetailed clinical assessmentNeurological soft signsSymptom Rating ScaleNegative Syndrome ScaleHigher AIMS scoresEvaluation ScaleNeurological deficitsExtrapyramidal symptomsClinical correlatesDeficit syndrome schizophreniaClinical evaluationClinical assessmentAIMS scoresLower PANSSMovement ScaleSoft signs
2007
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Tran-Johnson T, Sack D, Marcus R, Auby P, McQuade R, Oren D. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2007, 68: 111-9. PMID: 17284138, DOI: 10.4088/jcp.v68n0115.Peer-Reviewed Original ResearchConceptsPrimary efficacy measureIntramuscular aripiprazoleIM haloperidolIM aripiprazoleAcute agitationAdverse eventsEfficacy measuresTreatment-emergent adverse eventsCommon adverse eventsPlacebo-controlled trialPlacebo-controlled studyControl of agitationSchizo-affective disorderDSM-IV diagnosisNegative Syndrome ScaleHaloperidol groupIntramuscular haloperidolExtrapyramidal symptomsMore patientsInitial dosingSchizophreniform disorderMean changePlaceboSecondary measuresPEC scores
2005
Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman MG, Arnold M, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL. Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. Journal Of Child And Adolescent Psychopharmacology 2005, 15: 869-884. PMID: 16379507, DOI: 10.1089/cap.2005.15.869.Peer-Reviewed Original ResearchConceptsSimpson-Angus Neurological Rating ScaleAbnormal Involuntary Movement ScaleAdverse eventsBody mass indexAcute trialTreatment-emergent adverse eventsTolerability of risperidoneCommon adverse eventsMost adverse eventsOpen-label extensionPlacebo-controlled trialMonths of treatmentUnanticipated adverse eventsSame adverse eventsLong-term safetyNeurological Rating ScaleOpen-label risperidoneRisperidone groupRisperidone therapyExtrapyramidal symptomsBlood assessmentMass indexPlacebo nonrespondersMovement ScaleLifetime diagnosis
2004
Severe Extrapyramidal Symptoms in a 3-Year-Old Boy After Accidental Ingestion of the New Antipsychotic Drug Aripiprazole
Schonberger R, Douglas L, Baum C. Severe Extrapyramidal Symptoms in a 3-Year-Old Boy After Accidental Ingestion of the New Antipsychotic Drug Aripiprazole. 2004, 114: 1743-1743. PMID: 15574656, DOI: 10.1542/peds.2004-1268.Peer-Reviewed Original Research
2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003, 54: 453-464. PMID: 12915290, DOI: 10.1016/s0006-3223(03)00321-4.Peer-Reviewed Original ResearchConceptsExtrapyramidal symptomsPlacebo-controlled trialShort-term efficacyTrial of olanzapineTreatment x time interactionGreater symptomatic improvementSymptom total scoreX time interactionGreater weight gainRepeated-measures analysisOlanzapine patientsSchizophrenic prodromeOlanzapine treatmentPlacebo patientsSymptomatic improvementAcute treatmentMore patientsOlanzapine 5Prodromal symptomsRoutine treatmentProdromal patientsProdromal phaseWeek 8Week 6Placebo
2001
Tolerability Profile of Atypical Antipsychotics in Children and Adolescents
Stigler K, Potenza M, McDougle C. Tolerability Profile of Atypical Antipsychotics in Children and Adolescents. Pediatric Drugs 2001, 3: 927-942. PMID: 11772153, DOI: 10.2165/00128072-200103120-00005.Peer-Reviewed Original ResearchConceptsUse of clozapineExtrapyramidal symptomsAtypical antipsychoticsBodyweight gainTolerability profileGlucose intoleranceBlood glucoseReceptor profileRisk of EPSAdverse effectsCommon adverse effectsLiver function studiesTreatment-refractory diseasePotential treatment optionReceptor interaction profilesOnset of maniaLack of evidenceQTc prolongationBaseline electrocardiogramTreatment optionsSeizure riskCardiovascular illnessClose monitoringClozapineAntipsychoticsQuantitative Morphology of the Caudate and Putamen in Patients With Cocaine Dependence
Jacobsen LK, Giedd JN, Gottschalk C, Kosten TR, Krystal JH. Quantitative Morphology of the Caudate and Putamen in Patients With Cocaine Dependence. American Journal Of Psychiatry 2001, 158: 486-489. PMID: 11229995, DOI: 10.1176/appi.ajp.158.3.486.Peer-Reviewed Original ResearchConceptsCocaine dependenceDopaminergic functionStriatal dopaminergic depletionTypical neuroleptic treatmentTotal brain volumeChronic cocaine dependenceCocaine-dependent subjectsChronic cocaine useStriatal hypertrophyExtrapyramidal symptomsNeuroleptic treatmentDopaminergic depletionHealthy subjectsBrain volumePutamen volumeCocaine useStriatal structuresCaudatePatientsPutamenHypertrophyMagnetic resonanceDeficitsQuantitative morphologySubjects
1998
Predictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis
1996
Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. Journal Of Nuclear Medicine 1996, 37: 11-5. PMID: 8543979.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsBenzamidesBrainContrast MediaCorpus StriatumDopamine AntagonistsDose-Response Relationship, DrugFeasibility StudiesHumansInfusions, IntravenousIodine RadioisotopesMalePiperazinesPyrrolidinesReceptors, DopamineReceptors, Dopamine D2Time FactorsTomography, Emission-Computed, Single-PhotonConceptsHealthy male subjectsContinuous infusionBrain activity levelsReceptor occupancyStriatal activityAntipsychotic agentsDopamine receptorsMale subjectsSerial venous blood samplesSide effect ratingsBrain time-activity curvesContinuous intravenous infusionExtrapyramidal side effectsStriatal dopamine receptorsVenous blood samplesDopamine receptor occupancySerial SPECT imagesClinical responseExtrapyramidal symptomsIntravenous infusionSerum prolactinAntipsychotic drugsBlood samplesSide effectsTime-activity curves
1995
Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
Mazure CM, Cellar JS, Bowers MB, Nelson JC, Takeshita J, Zigun B. Assessment of extrapyramidal symptoms during acute neuroleptic treatment. The Journal Of Clinical Psychiatry 1995, 56: 94-100. PMID: 7883736.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAkathisia, Drug-InducedAntipsychotic AgentsBasal Ganglia DiseasesDystoniaFemaleHumansMaleMiddle AgedParkinson Disease, SecondaryPhysical ExaminationPsychiatric Status Rating ScalesPsychotic DisordersReproducibility of ResultsSeverity of Illness IndexStatistics, NonparametricConceptsExtrapyramidal symptomsDrug regimenAcute treatmentNeuroleptic drugsSide effectsInterrater reliabilityAcute neuroleptic treatmentPatient's drug regimenExtrapyramidal Symptoms ScaleExtrapyramidal side effectsTraditional neuroleptic drugsLow nonsignificant correlationsRatings of symptomsAcute administrationNeuroleptic treatmentAdverse reactionsParkinson's diseasePsychotic symptomsSymptom ScalePsychotic patientsEPS scaleSymptomsClinician ratersCliniciansInterrater agreement
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply